| 8.61 0.02 (0.23%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.05 | 1-year : | 11.74 |
| Resists | First : | 8.6 | Second : | 10.05 |
| Pivot price | 8.57  |
|||
| Supports | First : | 8.54 | Second : | 8.51 |
| MAs | MA(5) : | 8.59 |
MA(20) : | 8.56 |
| MA(100) : | 5.69 |
MA(250) : | 7.61 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 95.8 | D(3) : | 94.2 |
| RSI | RSI(14): 81.2 | |||
| 52-week | High : | 16.11 | Low : | 3.54 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ YMAB ] has closed below upper band by 9.6%. Bollinger Bands are 94.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.62 - 8.67 | 8.67 - 8.7 |
| Low: | 8.51 - 8.55 | 8.55 - 8.59 |
| Close: | 8.54 - 8.61 | 8.61 - 8.67 |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Mon, 01 Sep 2025
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
Thu, 14 Aug 2025
Y-mAbs Therapeutics’ SWOT analysis: acquisition shakes up oncology stock outlook - Investing.com
Tue, 12 Aug 2025
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock - Yahoo Finance
Thu, 07 Aug 2025
Y-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings Call - Quiver Quantitative
Thu, 07 Aug 2025
Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc. - Mayer Brown
Wed, 06 Aug 2025
Y-mAbs Therapeutics: Deal Showcases Value And Challenges Of Biotech M&A (YMAB) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 82.7 (%) |
| Shares Short | 1,850 (K) |
| Shares Short P.Month | 2,230 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.92 |
| Profit Margin | -26.1 % |
| Operating Margin | -28.8 % |
| Return on Assets (ttm) | -8.7 % |
| Return on Equity (ttm) | -24.4 % |
| Qtrly Rev. Growth | -14.4 % |
| Gross Profit (p.s.) | 1.53 |
| Sales Per Share | 1.87 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -17.22 |
| PEG Ratio | 0 |
| Price to Book value | 4.46 |
| Price to Sales | 4.58 |
| Price to Cash Flow | -21.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|